Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- JMACCT to Determine Number of Patients Seen by Each Institution by Disease
September 5, 2005
- BUSINESS NEWS IN BRIEF
September 5, 2005
- New Regenerative Therapy Using Cell Sheets Reported: Dr Okano
September 5, 2005
- Merger Preparations Going Smoothly: Sumitomo Pharm.
September 5, 2005
- SMOs Expected to Outpace CROs in Future Growth: Seminar
September 5, 2005
- Takeda Preparing to Launch Rozerem in US
September 5, 2005
- R&D NEWS IN BRIEF
September 5, 2005
- REGULATORY NEWS IN BRIEF
September 5, 2005
- Fuji Biomedix Debuts on NSE's Centrex Market
September 5, 2005
- Manifestos Published by Major Political Parties
September 5, 2005
- Korosho to Start Model Project to Prevent Metabolic Syndrome
September 5, 2005
- Insurance Premium Must Be Main Financial Resource for Healthcare Services: Seminar
September 5, 2005
- 1st Hyperuricemia/Metabolic Syndrome Forum Stresses Importance of Reduction in Multiple Risk Factors
September 5, 2005
- CDFS Recommends Approval of Candesartan for Chronic Heart Failure
September 5, 2005
- NEW PRODUCTD
September 5, 2005
- Institute Surveys Drug Expenditure Control Measures in 4 Major Countries
September 5, 2005
- PMDA Establishes Study Committee on Clinical Trials
September 5, 2005
- Current Gap Between NHI Prices and Market Prices 7-8%?
September 5, 2005
- NEW PRODUCTS
August 29, 2005
- 1st Half Business Results
August 29, 2005
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…